- Home
- STEW vs NEO Comparison
STEW vs NEO Comparison
Compare STEW & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | NEO |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 1996 | 2008 |
Fundamental Metrics
Financial Performance| Metric | STEW | NEO |
|---|---|---|
| Price | $18.20 | $18.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 54.9K | ★ 1.5M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.55 | $7.07 |
| 52 Week High | $19.05 | $19.76 |
Technical Indicators
Market Signals| Indicator | STEW | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 65.23 |
| Support Level | $18.27 | $16.87 |
| Resistance Level | $18.54 | $19.76 |
| Average True Range (ATR) | 0.16 | 0.87 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 32.14 | 60.18 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.